WO2001029036A3 - Allosteric sites on muscarinic receptors - Google Patents

Allosteric sites on muscarinic receptors Download PDF

Info

Publication number
WO2001029036A3
WO2001029036A3 PCT/GB2000/004064 GB0004064W WO0129036A3 WO 2001029036 A3 WO2001029036 A3 WO 2001029036A3 GB 0004064 W GB0004064 W GB 0004064W WO 0129036 A3 WO0129036 A3 WO 0129036A3
Authority
WO
WIPO (PCT)
Prior art keywords
binding
muscarinic receptors
allosteric sites
receptors
compounds
Prior art date
Application number
PCT/GB2000/004064
Other languages
French (fr)
Other versions
WO2001029036A2 (en
Inventor
Nigel Birdsall
Sebastian Lazareno
Original Assignee
Medical Res Council Technology
Nigel Birdsall
Sebastian Lazareno
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical Res Council Technology, Nigel Birdsall, Sebastian Lazareno filed Critical Medical Res Council Technology
Priority to JP2001531835A priority Critical patent/JP2003512607A/en
Priority to EP00971543A priority patent/EP1222463A2/en
Priority to CA002386149A priority patent/CA2386149A1/en
Priority to AU10383/01A priority patent/AU779391B2/en
Publication of WO2001029036A2 publication Critical patent/WO2001029036A2/en
Publication of WO2001029036A3 publication Critical patent/WO2001029036A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • G01N33/944—Acetylcholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70571—Assays involving receptors, cell surface antigens or cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Anesthesiology (AREA)

Abstract

An allosteric site on muscarinic receptors is disclosed, together with its use for screening for compounds capable of modulating the binding of a primary ligand such as acetylcholine to the receptor. The site is characterised herein a series of indolocarbazoles represented by formula (1) and a series of related compounds represented by formula (2). These compounds are capable of binding to the allosteric site to modulate the binding of a primary ligand to the receptors, showing positive, negative and neutral cooperativity and selectivity for muscarinic receptor subtypes.
PCT/GB2000/004064 1999-10-21 2000-10-20 Allosteric sites on muscarinic receptors WO2001029036A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2001531835A JP2003512607A (en) 1999-10-21 2000-10-20 Allosteric site of muscarinic receptor
EP00971543A EP1222463A2 (en) 1999-10-21 2000-10-20 Allosteric sites on muscarinic receptors
CA002386149A CA2386149A1 (en) 1999-10-21 2000-10-20 Allosteric sites on muscarinic receptors
AU10383/01A AU779391B2 (en) 1999-10-21 2000-10-20 Allosteric sites on muscarinic receptors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9924962.5 1999-10-21
GBGB9924962.5A GB9924962D0 (en) 1999-10-21 1999-10-21 Allosteric sites on muscarinic receptors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US09/886,882 Continuation US6382257B2 (en) 1999-10-20 2001-06-21 Fluid control system

Publications (2)

Publication Number Publication Date
WO2001029036A2 WO2001029036A2 (en) 2001-04-26
WO2001029036A3 true WO2001029036A3 (en) 2002-05-10

Family

ID=10863158

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2000/004064 WO2001029036A2 (en) 1999-10-21 2000-10-20 Allosteric sites on muscarinic receptors

Country Status (6)

Country Link
EP (1) EP1222463A2 (en)
JP (1) JP2003512607A (en)
AU (1) AU779391B2 (en)
CA (1) CA2386149A1 (en)
GB (1) GB9924962D0 (en)
WO (1) WO2001029036A2 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8865735B2 (en) 2011-02-21 2014-10-21 Hoffman-La Roche Inc. Solid forms of a pharmaceutically active substance
US9096593B2 (en) 2009-11-06 2015-08-04 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
US9169250B2 (en) 2006-11-22 2015-10-27 Plexxikon Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
US9447089B2 (en) 2009-04-03 2016-09-20 Plexxikon Inc. Compositions and uses thereof
US9469640B2 (en) 2007-07-17 2016-10-18 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004084889A1 (en) * 2003-03-28 2004-10-07 Pfizer Inc. Use of protein kinase c inhibitor for suppressing sustained slow postsynaptic excitation (sspe) of enteric neurons
CA2583550C (en) * 2004-10-25 2013-05-14 Eli Lily And Company Thienopyridines as allosteric potentiators of the m4 muscarinic receptor
WO2007002670A2 (en) * 2005-06-28 2007-01-04 Bausch & Lomb Incorporated Method of lowering intraocular pressure
MA34948B1 (en) 2011-02-07 2014-03-01 Plexxikon Inc COMPOUNDS AND METHODS FOR MODULATING KINASE, AND INDICATIONS THEREOF

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996003377A1 (en) * 1994-07-27 1996-02-08 Sankyo Company, Limited Heterocyclic compounds, useful as allosteric effectors at muscarinic receptors
GB2292685A (en) * 1994-07-27 1996-03-06 Sankyo Co Allosteric effectors at muscarinic receptors
WO1996013506A1 (en) * 1994-10-26 1996-05-09 Cephalon, Inc. Protein kinase inhibitors for treatment of neurological disorders
US5658898A (en) * 1994-11-09 1997-08-19 Ciba Geigy Corporation Intravenous solutions for a derivative of staurosporine
US5677327A (en) * 1995-06-22 1997-10-14 Allergan Method for identifying muscarinic agents lacking miotic side effects
US5747336A (en) * 1988-09-08 1998-05-05 The United States Of America As Represented By The Department Of Health And Human Services Cloned human genes for muscarinic acetylcholine receptors and cells lines expressing same

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747336A (en) * 1988-09-08 1998-05-05 The United States Of America As Represented By The Department Of Health And Human Services Cloned human genes for muscarinic acetylcholine receptors and cells lines expressing same
WO1996003377A1 (en) * 1994-07-27 1996-02-08 Sankyo Company, Limited Heterocyclic compounds, useful as allosteric effectors at muscarinic receptors
GB2292685A (en) * 1994-07-27 1996-03-06 Sankyo Co Allosteric effectors at muscarinic receptors
WO1996013506A1 (en) * 1994-10-26 1996-05-09 Cephalon, Inc. Protein kinase inhibitors for treatment of neurological disorders
US5658898A (en) * 1994-11-09 1997-08-19 Ciba Geigy Corporation Intravenous solutions for a derivative of staurosporine
US5677327A (en) * 1995-06-22 1997-10-14 Allergan Method for identifying muscarinic agents lacking miotic side effects

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BIRDSALL NIGEL J M ET AL: "Subtype-selective positive cooperative interactions between brucine analogs and acetylcholine at muscarinic receptors: Functional studies.", MOLECULAR PHARMACOLOGY, vol. 55, no. 4, April 1999 (1999-04-01), pages 778 - 787, XP000997267, ISSN: 0026-895X *
LAZARENO S ET AL: "Allosteric effects of four stereoisomers of a fused indole ring system with 3H-N-methylscopolamine and acetylcholine at M1-M4 muscarinic receptors.", LIFE SCIENCES, vol. 64, no. 6-7, 8 January 1999 (1999-01-08), Eighth International Symposium on Subtypes of Muscarinic Receptors;Danvers, Massachusetts, USA; August 25-29, 1998, pages 519 - 526, XP000997312, ISSN: 0024-3205 *
LAZARENO S ET AL: "Subtype-selective positive cooperative interactions between brucine analogues and acetylcholine at muscarinic receptors: Radioligand binding studies.", MOLECULAR PHARMACOLOGY, vol. 53, no. 3, March 1998 (1998-03-01), pages 573 - 589, XP000997226, ISSN: 0026-895X *
LAZARENO SEBASTIAN ET AL: "Allosteric interactions of staurosporine and other indolocarbazoles with N-(methyl-3H)scopolamine and acetylcholine at muscarinic receptor subtypes: Identification of a second allosteric site.", MOLECULAR PHARMACOLOGY, vol. 58, no. 1, July 2000 (2000-07-01), pages 194 - 206, XP000997198, ISSN: 0026-895X *
LAZARENO SEBASTIAN ET AL: "Detection, quantitation and verification of allosteric interactions of agents with labeled and unlabeled ligands at G protein-coupled receptors: Interactions of strychnine and acetylcholine at muscarinic receptors.", MOLECULAR PHARMACOLOGY, vol. 48, no. 2, 1995, pages 362 - 378, XP000997227, ISSN: 0026-895X *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9169250B2 (en) 2006-11-22 2015-10-27 Plexxikon Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
US9487515B2 (en) 2006-11-22 2016-11-08 Plexxikon Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
US9469640B2 (en) 2007-07-17 2016-10-18 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
US9447089B2 (en) 2009-04-03 2016-09-20 Plexxikon Inc. Compositions and uses thereof
US9096593B2 (en) 2009-11-06 2015-08-04 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
US8865735B2 (en) 2011-02-21 2014-10-21 Hoffman-La Roche Inc. Solid forms of a pharmaceutically active substance
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds

Also Published As

Publication number Publication date
WO2001029036A2 (en) 2001-04-26
AU779391B2 (en) 2005-01-20
GB9924962D0 (en) 1999-12-22
JP2003512607A (en) 2003-04-02
CA2386149A1 (en) 2001-04-26
AU1038301A (en) 2001-04-30
EP1222463A2 (en) 2002-07-17

Similar Documents

Publication Publication Date Title
WO2001029036A3 (en) Allosteric sites on muscarinic receptors
MX9700696A (en) Heterocyclic compounds, useful as allosteric effectors at muscarinic receptors.
BG106301A (en) Quinuclidine derivatives and their use as muscarinic m3 receptor ligands
CA2256479A1 (en) Novel photochromic heterocyclic fused indenonaphthopyrans
DE69936100D1 (en) SOMATOSTATIN ANALOGUE WITH A CYCLED CONFORMATION RESTRICTED CHAIN
EP0786926A3 (en) Light-emitting material for organo-electroluminescence device and organo-electroluminescence devive for which the light-emitting material is adapted
CA2278139A1 (en) Novel photochromic heterocyclic fused indenonaphthopyrans
FI945486A (en) Metallocenes, process for their preparation and their use as catalysts
AP9801312A0 (en) 4-aminopyrrole (3,2-d) pyrimidines as neuropeptide y receptor anatagonist.
BR0010215A (en) Indoline derivatives as progesterone antagonists
NO20051328L (en) Calcium receptor modulating compound and its use
TR199902372A2 (en) Who sulfanylsilane.
BR9809092A (en) Indole derivatives having combined 5ht1a, 5ht1b and 5ht1d receptor antagonist activity
EA200000372A1 (en) CYCLOPENTENE DERIVATIVES, USEFUL AS ANTAGONISTS OF MOTILIN RECEPTOR
TR199700799T1 (en) Transdermal form�lasyon.
EP0358200A3 (en) Polymer compositions stabilized with polysiloxanes containing sterically hindered heterocyclic moiety
EP0681583A1 (en) Tricyclic heterocyclic compounds as 5-ht4 receptor antagonists.
ATE219486T1 (en) TRICYCLIC INDOLE-2-CARBONIC ACID DERIVATIVES AS SELECTIVE NMDA RECEPTOR ANTAGONISTS
AU6979494A (en) Azacyclic-heterocyclic compounds as angiotensin ii receptor antagonists
DE60121536D1 (en) Copolymer, this containing adhesive and laminate
WO1999033841A3 (en) Pyrrolothiazine and pyrrolothiazepine compounds having serotonin-2 receptor antagonistic and alpha-1-blocking action
WO2001044439A3 (en) Glucocorticoid induced receptor (hgir,rp-23) ligand screening
JPS5389104A (en) Rug rubber laid under joint of rails for heavy load railway
PT72582A (en) NEUE CEPHALOSPORINE VERFAHREN ZU IHRER HERSTELLUNG UND DIESE VERBINDUNGEN ENTHALTENDE ARZNEIMITTEL
AU678978B2 (en) Receptor derivates with binding sites for human rhinoviruses

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 09886882

Country of ref document: US

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2000971543

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2386149

Country of ref document: CA

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 531835

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 10383/01

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2000971543

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 10383/01

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 2000971543

Country of ref document: EP